# US 2026/0085070 A1 · Heterocyclic cbl-b inhibitors for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085070 A1
- Document ID: US20260085070A1
- Status: Published application
- Kind: A1
- Application number: 19/171,907
- Filed: 2025-04-07
- Published: 2026-03-26
- Earliest claimed: 2022-10-19
- Assignees: Hotspot Therapeutics, Inc.
- Applicants: Hotspot Therapeutics, Inc.
- Inventors: Yingzhi BI; Kenneth G. CARSON; Geraldine Cirillo HARRIMAN
- Web page: https://patentgrep.com/patent/US20260085070A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.

## Claims

### Claim 1

A compound of formula (A):
or pharmaceutically acceptable salts thereof,
wherein
X is optionally substituted phenyl or optionally substituted 5-6 membered heteroaryl;
Y is —N═ or —C(H)═;
R* is selected from the group consisting of —CH2-A, —CH2—O-A, —CH2—O—CH2-A, —CH2N(H)-A, —CH(CH3)N(H)-A, and —CH2N(H)CH2-A;
Rb is selected from the group consisting of hydrogen, halogen, —OR1, and optionally substituted C1-C3 alkyl;
Rc is optionally substituted C1-C3 alkyl;
Rd is selected from the group consisting of hydrogen, halogen, optionally substituted C3-C7 carbocylyl, —OR1, and —NR1R2;
Re is hydrogen or halogen;
A is selected from the group consisting of —OH, —OR1, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C7 carbocylyl, and optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, wherein A is optionally substituted with 1-5 instances of Ra1;
each Ra1 is independently selected from the group consisting of halogen, —CN, —OH, —OR1, —NH2, —NR1R2, —SH, —SR1, —SF5, —CO2H, —CO2R1, —CONH2, —CONR1R2, —SO2NH2, —SO2NR1R2, —SO2OH, —SO2OR1, —S(O)R1, —S(O)2R1, —S(O)(NH)R1, —S(O)(NR1)R1, optionally substituted C1-C6 aliphatic, optionally substituted C1-C6 heteroalkyl, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted phenyl, and optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S,
wherein two instances of Ra1 are optionally taken together to form an optionally substituted C3-C7 carbocylyl or optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S;
each R1 is independently selected from the group consisting of optionally substituted C1-C6 aliphatic, optionally substituted phenyl, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S, —C(O)R3, —CO2R3, —C(O)NHR3, and —SO2R3;
each R2 is independently selected from the group consisting of hydrogen, optionally substituted C1-C6 aliphatic, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted phenyl, and optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S;
or R1 and R2 are taken together with their intervening atom(s) to form a 3-8-membered heterocyclyl ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S, or an optionally substituted 5-6-membered heteroaryl ring containing 1-4 heteroatoms selected from the group consisting of N, O, and S; and
each R3 is independently selected from the group consisting of optionally substituted C1-C6 aliphatic, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted phenyl, optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Rc is —CH3 or —CHF2.

### Claim 3 (depends on 2)

The compound of claim 2, wherein Rc is —CHF2.

### Claim 4 (depends on 2)

The compound of claim 2, wherein Rc is —CH3.

### Claim 5 (depends on 1)

The compound of claim 1, wherein X is optionally substituted C1-C2 alkylene.

### Claim 6 (depends on 1)

The compound of claim 1, wherein X is optionally substituted optionally substituted phenyl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein X is optionally substituted 5-membered heteroaryl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein X is optionally substituted 6-membered heteroaryl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein X is optionally substituted pyrazole.

### Claim 10 (depends on 1)

The compound of claim 1, wherein X is selected from the group consisting of

### Claim 11 (depends on 1)

The compound of claim 1, wherein Ra is selected from the group consisting of —CH2N(H)-A, —CH(CH3)N(H)-A, and —CH2N(H)CH2-A.

### Claim 12 (depends on 1)

The compound of claim 1, wherein Ra is selected from the group consisting of —CH2-A, —CH2—O-A, and —CH2—O—CH2-A.

### Claim 13 (depends on 11)

The compound of claim 11, wherein A is optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S.

### Claim 14 (depends on 11)

The compound of claim 11, wherein A is optionally substituted 3-6 membered carbocylyl.

### Claim 15 (depends on 1)

The compound of claim 1, wherein Ra is selected from the group consisting of —CH2OH, —CH2N(H)CH2CH2OCH3,

### Claim 16 (depends on 1)

The compound of claim 1, wherein Rb is halogen.

### Claim 17 (depends on 16)

The compound of claim 16, wherein Rb is chloro.

### Claim 18 (depends on 1)

The compound of claim 1, wherein Rb is optionally substituted C1 alkyl.

### Claim 19 (depends on 1)

The compound of claim 1, wherein Rb selected from the group consisting of chloro, —CF3, and —CHF2,

### Claim 20

A compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable adjuvant or carrier.

### Claim at position 22

22-33. (canceled)
